Drug Trial Radar · NCT04284917
Long-term Efficacy of Carglumic Acid in Organic Acidemia.
Last checked: Nov 20, 2026Latest source record: Mar 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
3
Actual
Start
Nov 28, 2019
Primary completion
Dec 31, 2024
Study completion Mar 11, 2025
Sponsor
- Lead sponsor
- National Taiwan University HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Feb 26, 2020
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 0 years, up to 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Evaluate the Long Term Effectiveness \& Safety of the use of Carglumic Acid (Carbaglu®) in Patients with Propionic Acidemia (PA) or Methylmalonic Acidemia (MMA).
Conditions
- Propionic Acidemia (PA) , Methylmalonic Acidemia (MMA)
Interventions
Carglumic Acid (Carbaglu®)Drug
A. Study period: 36 months; treatment period: 12 months. B. Patients will receive Carglumic Acid (Carbaglu®) 50 mg/kg/day in addition to standard therapy (protein restricted diet, L-carnitine, metronidazole and vitamin B12). C. Patients need to regularly come back for follow up examination on Day 0, month 3, month 6, and month 12. D. Patients should report any adverse event that occur during treatment period. E. Patients' number of emergency visits due to hyperammonemia, ammonia level, acylcarnitine, urinary organic acid analysis, plasma amino acid analysis and methylmalonic acid will be recorded during treatment period.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of emergency visits due to hyperammonemia within 12 months periodTime frame: 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
National Taiwan University Hospital
Taipei, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.